Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Discoidin domains in receptor tyrosine kinases.

Fridman R, Agarwal G.

Biochim Biophys Acta Mol Cell Res. 2019 Aug 7:118527. doi: 10.1016/j.bbamcr.2019.118527. [Epub ahead of print] No abstract available.

PMID:
31400359
2.

Live cell measurements of interaction forces and binding kinetics between Discoidin Domain Receptor DDR1 and collagen I with atomic force microscopy.

Sarkar A, Sohail A, Dong J, Prunotto M, Shinki K, Fridman R, Hoffmann PM.

Biochim Biophys Acta Gen Subj. 2019 Jul 24;1863(11):129402. doi: 10.1016/j.bbagen.2019.07.011. [Epub ahead of print]

PMID:
31351093
3.

Discoidin domain receptors: A promising target in melanoma.

Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, Pages C, Mazouz Dorval S, Marco O, Menashi S, Fridman R, Lebbé C, Mourah S, Jouenne F.

Pigment Cell Melanoma Res. 2019 Sep;32(5):697-707. doi: 10.1111/pcmr.12809. Epub 2019 Jul 22.

PMID:
31271515
4.

Characterization and regulation of MT1-MMP cell surface-associated activity.

Pahwa S, Bhowmick M, Amar S, Cao J, Strongin AY, Fridman R, Weiss SJ, Fields GB.

Chem Biol Drug Des. 2019 Jun;93(6):1251-1264. doi: 10.1111/cbdd.13450. Epub 2018 Dec 19.

PMID:
30480376
5.

Clustering, Spatial Distribution, and Phosphorylation of Discoidin Domain Receptors 1 and 2 in Response to Soluble Collagen I.

Yeung DA, Shanker N, Sohail A, Weiss BA, Wang C, Wellmerling J, Das S, Ganju RK, Miller JLC, Herr AB, Fridman R, Agarwal G.

J Mol Biol. 2019 Jan 18;431(2):368-390. doi: 10.1016/j.jmb.2018.11.015. Epub 2018 Nov 17.

PMID:
30458172
6.

DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

Richter H, Satz AL, Bedoucha M, Buettelmann B, Petersen AC, Harmeier A, Hermosilla R, Hochstrasser R, Burger D, Gsell B, Gasser R, Huber S, Hug MN, Kocer B, Kuhn B, Ritter M, Rudolph MG, Weibel F, Molina-David J, Kim JJ, Santos JV, Stihle M, Georges GJ, Bonfil RD, Fridman R, Uhles S, Moll S, Faul C, Fornoni A, Prunotto M.

ACS Chem Biol. 2019 Jan 18;14(1):37-49. doi: 10.1021/acschembio.8b00866. Epub 2018 Dec 16.

7.

Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.

Moll S, Yasui Y, Abed A, Murata T, Shimada H, Maeda A, Fukushima N, Kanamori M, Uhles S, Badi L, Cagarelli T, Formentini I, Drawnel F, Georges G, Bergauer T, Gasser R, Bonfil RD, Fridman R, Richter H, Funk J, Moeller MJ, Chatziantoniou C, Prunotto M.

J Transl Med. 2018 Jun 1;16(1):148. doi: 10.1186/s12967-018-1524-5.

9.

Preface - Matrix metalloproteinases.

Fridman R.

Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):1925-1926. doi: 10.1016/j.bbamcr.2017.07.007. Epub 2017 Jul 22. No abstract available.

10.

Medication adherence as a predictor of 30-day hospital readmissions.

Rosen OZ, Fridman R, Rosen BT, Shane R, Pevnick JM.

Patient Prefer Adherence. 2017 Apr 20;11:801-810. doi: 10.2147/PPA.S125672. eCollection 2017.

11.

SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.

Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D.

J Med Chem. 2015 Aug 13;58(15):5808-24. doi: 10.1021/acs.jmedchem.5b00354. Epub 2015 Aug 4.

12.

Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.

Toy KA, Valiathan RR, Núñez F, Kidwell KM, Gonzalez ME, Fridman R, Kleer CG.

Breast Cancer Res Treat. 2015 Feb;150(1):9-18. doi: 10.1007/s10549-015-3285-7. Epub 2015 Feb 10.

13.

Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition.

Koh M, Woo Y, Valiathan RR, Jung HY, Park SY, Kim YN, Kim HR, Fridman R, Moon A.

Int J Cancer. 2015 Mar 15;136(6):E508-20. doi: 10.1002/ijc.29154. Epub 2014 Aug 30.

14.

TIMP-1 via TWIST1 induces EMT phenotypes in human breast epithelial cells.

D'Angelo RC, Liu XW, Najy AJ, Jung YS, Won J, Chai KX, Fridman R, Kim HR.

Mol Cancer Res. 2014 Sep;12(9):1324-33. doi: 10.1158/1541-7786.MCR-14-0105. Epub 2014 Jun 3.

15.

Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.

Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD.

Int J Cancer. 2015 Jan 1;136(1):11-20. doi: 10.1002/ijc.28948. Epub 2014 May 20.

16.

Glycosylation at Asn211 regulates the activation state of the discoidin domain receptor 1 (DDR1).

Fu HL, Valiathan RR, Payne L, Kumarasiri M, Mahasenan KV, Mobashery S, Huang P, Fridman R.

J Biol Chem. 2014 Mar 28;289(13):9275-87. doi: 10.1074/jbc.M113.541102. Epub 2014 Feb 7.

17.

Imaging of diabetic foot infections.

Fridman R, Bar-David T, Kamen S, Staron RB, Leung DK, Rasiej MJ.

Clin Podiatr Med Surg. 2014 Jan;31(1):43-56. doi: 10.1016/j.cpm.2013.09.002. Review.

PMID:
24296017
18.

Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB.

Dilly AK, Ekambaram P, Guo Y, Cai Y, Tucker SC, Fridman R, Kandouz M, Honn KV.

Int J Cancer. 2013 Oct 15;133(8):1784-91. doi: 10.1002/ijc.28165. Epub 2013 Jul 13. Erratum in: Int J Cancer. 2019 Oct 1;145(7):E20.

19.

Shedding of discoidin domain receptor 1 by membrane-type matrix metalloproteinases.

Fu HL, Sohail A, Valiathan RR, Wasinski BD, Kumarasiri M, Mahasenan KV, Bernardo MM, Tokmina-Roszyk D, Fields GB, Mobashery S, Fridman R.

J Biol Chem. 2013 Apr 26;288(17):12114-29. doi: 10.1074/jbc.M112.409599. Epub 2013 Mar 21.

20.

Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases.

Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A.

Cancer Biol Ther. 2013 May;14(5):417-27. doi: 10.4161/cbt.23762. Epub 2013 Feb 4.

21.

Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling.

Fu HL, Valiathan RR, Arkwright R, Sohail A, Mihai C, Kumarasiri M, Mahasenan KV, Mobashery S, Huang P, Agarwal G, Fridman R.

J Biol Chem. 2013 Mar 15;288(11):7430-7. doi: 10.1074/jbc.R112.444158. Epub 2013 Jan 18. Review.

22.

TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain.

Jung YS, Liu XW, Chirco R, Warner RB, Fridman R, Kim HR.

PLoS One. 2012;7(6):e38773. doi: 10.1371/journal.pone.0038773. Epub 2012 Jun 11.

23.

Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography.

Toth M, Sohail A, Fridman R.

Methods Mol Biol. 2012;878:121-35. doi: 10.1007/978-1-61779-854-2_8.

PMID:
22674130
24.

Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection.

Fridman R, Benton G, Aranoutova I, Kleinman HK, Bonfil RD.

Nat Protoc. 2012 May 17;7(6):1138-44. doi: 10.1038/nprot.2012.053.

PMID:
22596226
25.

Discoidin domain receptor tyrosine kinases: new players in cancer progression.

Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R.

Cancer Metastasis Rev. 2012 Jun;31(1-2):295-321. doi: 10.1007/s10555-012-9346-z. Review.

26.

PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.

Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28.

27.

Characterization of the dimerization interface of membrane type 4 (MT4)-matrix metalloproteinase.

Sohail A, Marco M, Zhao H, Shi Q, Merriman S, Mobashery S, Fridman R.

J Biol Chem. 2011 Sep 23;286(38):33178-89. doi: 10.1074/jbc.M111.253369. Epub 2011 Aug 2.

28.

Hammer toe, mallet toe, and claw toe.

Angirasa AK, Augoyard M, Coughlin MJ, Fridman R, Ruch J, Weil L Jr.

Foot Ankle Spec. 2011 Jun;4(3):182-7. doi: 10.1177/1938640011409010. No abstract available.

PMID:
21697399
29.

Bimodal regulation of FoxO3 by AKT and 14-3-3.

Dobson M, Ramakrishnan G, Ma S, Kaplun L, Balan V, Fridman R, Tzivion G.

Biochim Biophys Acta. 2011 Aug;1813(8):1453-64. doi: 10.1016/j.bbamcr.2011.05.001. Epub 2011 May 19.

30.

Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A.

Eur J Med Chem. 2011 Jul;46(7):2617-29. doi: 10.1016/j.ejmech.2011.03.033. Epub 2011 Apr 2.

31.

Dissociation kinetics of an enzyme-inhibitor system using single-molecule force measurements.

Mayyas E, Bernardo M, Runyan L, Sohail A, Subba-Rao V, Pantea M, Fridman R, Hoffmann PM.

Biomacromolecules. 2010 Dec 13;11(12):3352-8. doi: 10.1021/bm100844x. Epub 2010 Oct 25.

PMID:
20973496
32.

Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.

Kim S, Huang W, Mottillo EP, Sohail A, Ham YA, Conley-Lacomb MK, Kim CJ, Tzivion G, Kim HR, Wang S, Chen YQ, Fridman R.

Biochim Biophys Acta. 2010 Nov;1803(11):1287-97. doi: 10.1016/j.bbamcr.2010.06.011. Epub 2010 Jul 8.

33.

Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.

Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, Cher ML.

Cancer Res. 2010 Jul 1;70(13):5558-66. doi: 10.1158/0008-5472.CAN-09-4416. Epub 2010 Jun 15.

34.

MT6-MMP is present in lipid rafts and faces inward in living human PMNs but translocates to the cell surface during neutrophil apoptosis.

Fortin CF, Sohail A, Sun Q, McDonald PP, Fridman R, Fülöp T.

Int Immunol. 2010 Aug;22(8):637-49. doi: 10.1093/intimm/dxq048. Epub 2010 May 25.

35.

Multidisciplinary peripheral arterial disease.

Fridman R, Bar-David T, Dayal R, Faintuch S, Goldin D, Hamdan A, Landsman A, Markinson B, Sperling D, Wyers M.

Foot Ankle Spec. 2010 Feb;3(1):35-9. doi: 10.1177/1938640009357018. No abstract available.

PMID:
20400439
36.

Matrix metalloproteinases.

Fridman R.

Biochim Biophys Acta. 2010 Jan;1803(1):1-2. doi: 10.1016/j.bbamcr.2010.01.016. No abstract available.

37.

Unilateral versus bilateral first ray surgery: a prospective study of 186 consecutive cases--patient satisfaction, cost to society, and complications.

Fridman R, Cain JD, Weil L Jr, Weil LS Sr, Ray TB.

Foot Ankle Spec. 2009 Jun;2(3):123-9. doi: 10.1177/1938640009335972.

PMID:
19825763
38.

Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors.

Gooyit M, Lee M, Hesek D, Boggess B, Oliver AG, Fridman R, Mobashery S, Chang M.

Chem Biol Drug Des. 2009 Dec;74(6):535-46. doi: 10.1111/j.1747-0285.2009.00898.x. Epub 2009 Oct 12.

39.

Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases.

Forbes C, Shi Q, Fisher JF, Lee M, Hesek D, Llarrull LI, Toth M, Gossing M, Fridman R, Mobashery S.

Chem Biol Drug Des. 2009 Dec;74(6):527-34. doi: 10.1111/j.1747-0285.2009.00881.x. Epub 2009 Oct 6.

40.

Extracorporeal shockwave therapy for interdigital neuroma: a randomized, placebo-controlled, double-blind trial.

Fridman R, Cain JD, Weil L Jr.

J Am Podiatr Med Assoc. 2009 May-Jun;99(3):191-3.

PMID:
19448168
41.

A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition.

Lee M, Celenza G, Boggess B, Blase J, Shi Q, Toth M, Bernardo MM, Wolter WR, Suckow MA, Hesek D, Noll BC, Fridman R, Mobashery S, Chang M.

Chem Biol Drug Des. 2009 Feb;73(2):189-202. doi: 10.1111/j.1747-0285.2008.00750.x.

42.

Extracorporeal shockwave therapy for the treatment of Achilles tendinopathies: a prospective study.

Fridman R, Cain JD, Weil L Jr, Weil L Sr.

J Am Podiatr Med Assoc. 2008 Nov-Dec;98(6):466-8.

PMID:
19017855
43.

Identification and role of the homodimerization interface of the glycosylphosphatidylinositol-anchored membrane type 6 matrix metalloproteinase (MMP25).

Zhao H, Sohail A, Sun Q, Shi Q, Kim S, Mobashery S, Fridman R.

J Biol Chem. 2008 Dec 12;283(50):35023-32. doi: 10.1074/jbc.M806553200. Epub 2008 Oct 20.

44.

Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?

Bonfil RD, Fridman R, Mobashery S, Cher ML.

Curr Oncol. 2008 Aug;15(4):188-92. No abstract available.

45.

Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach.

Xu D, Suenaga N, Edelmann MJ, Fridman R, Muschel RJ, Kessler BM.

Mol Cell Proteomics. 2008 Nov;7(11):2215-28. doi: 10.1074/mcp.M800095-MCP200. Epub 2008 Jul 2.

46.

The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP.

Cho JA, Osenkowski P, Zhao H, Kim S, Toth M, Cole K, Aboukameel A, Saliganan A, Schuger L, Bonfil RD, Fridman R.

J Biol Chem. 2008 Jun 20;283(25):17391-405. doi: 10.1074/jbc.M708943200. Epub 2008 Apr 15.

47.

MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer.

Sohail A, Sun Q, Zhao H, Bernardo MM, Cho JA, Fridman R.

Cancer Metastasis Rev. 2008 Jun;27(2):289-302. doi: 10.1007/s10555-008-9129-8. Review.

48.

Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.

Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A.

Cancer Res. 2007 Dec 15;67(24):11760-8.

49.

Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma.

Rosenblum G, Meroueh S, Toth M, Fisher JF, Fridman R, Mobashery S, Sagi I.

J Am Chem Soc. 2007 Nov 7;129(44):13566-74. Epub 2007 Oct 12.

PMID:
17929919
50.

Metabolism of a highly selective gelatinase inhibitor generates active metabolite.

Lee M, Villegas-Estrada A, Celenza G, Boggess B, Toth M, Kreitinger G, Forbes C, Fridman R, Mobashery S, Chang M.

Chem Biol Drug Des. 2007 Nov;70(5):371-82. Epub 2007 Oct 10.

PMID:
17927722

Supplemental Content

Loading ...
Support Center